05:37 PM EST, 01/14/2025 (MT Newswires) -- Context Therapeutics ( CNTX ) said Tuesday it dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.

Initial data from the trial is expected to be released in H1 2026, the company said.

The phase 1 trial seeks to evaluate the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer.

Up to 70 patients will be enrolled in the phase 1 trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity, including response rate, duration, and disease control, the company said.

Shares of Context Therapeutics ( CNTX ) were up 1% in after-hours activity.